Review



mouse pf4 elisa kit  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Elabscience Biotechnology mouse pf4 elisa kit
    TLR8 agonist activates <t>PF4-CXCR3</t> pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01
    Mouse Pf4 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+PF4+(Platelet+Factor+4)+ELISA+Kit/pmc12901762-237-8-12
    Average 94 stars, based on 6 article reviews
    mouse pf4 elisa kit - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms"

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms

    Journal: Cancer Immunology, Immunotherapy : CII

    doi: 10.1007/s00262-026-04329-8

    TLR8 agonist activates PF4-CXCR3 pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01
    Figure Legend Snippet: TLR8 agonist activates PF4-CXCR3 pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01

    Techniques Used: Control, Marker, Expressing, Gene Expression, Quantitative Proteomics

    TLR8 agonist induces PF4 expression through NF-κB signaling pathway. A , B qRT-PCR analysis of Pf4 expression in mouse and human macrophages in the motolimod-treated and control groups ( n = 3). C , D Luminescence assay showing NF-κB pathway activation in mouse and human macrophages following motolimod stimulation ( n = 3). E , F qRT-PCR analysis of Rela expression in Rela -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). G , H Western blotting showing p65 protein levels in RELA -knockdown and control mouse and human macrophages with or without motolimod treatment. I , J qRT-PCR analysis of Pf4 / PF4 expression in Rela / RELA -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). K ELISA quantification of Pf4 levels in the culture supernatant from Rela -knockdown and control mouse macrophages with or without motolimod treatment ( n = 3). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001
    Figure Legend Snippet: TLR8 agonist induces PF4 expression through NF-κB signaling pathway. A , B qRT-PCR analysis of Pf4 expression in mouse and human macrophages in the motolimod-treated and control groups ( n = 3). C , D Luminescence assay showing NF-κB pathway activation in mouse and human macrophages following motolimod stimulation ( n = 3). E , F qRT-PCR analysis of Rela expression in Rela -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). G , H Western blotting showing p65 protein levels in RELA -knockdown and control mouse and human macrophages with or without motolimod treatment. I , J qRT-PCR analysis of Pf4 / PF4 expression in Rela / RELA -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). K ELISA quantification of Pf4 levels in the culture supernatant from Rela -knockdown and control mouse macrophages with or without motolimod treatment ( n = 3). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Techniques Used: Expressing, Quantitative RT-PCR, Control, Luminescence Assay, Activation Assay, Knockdown, Western Blot, Enzyme-linked Immunosorbent Assay

    PF4 remodels the TIME and suppresses tumor growth. A , B Tumor growth curves and terminal tumor weights in C57BL/6 mice bearing AKR or MC38 tumors with or without Pf4 overexpression, treated with or without motolimod administered every three days ( n = 6). C Percentage of CD45 + cells among live cells in AKR and MC38 tumor models ( n = 6). D Percentage of cCD4 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). E Percentage of CD8 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). F Percentage of Tregs within the CD45 + population in AKR and MC38 tumor models ( n = 6). G Ratios of cCD4 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). H Ratios of CD8 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). I Representative immunofluorescence staining of CD8α (red) and DAPI (blue) in MC38-Vector or MC38-Pf4-OE tumor sections with or without motolimod treatment. Scale bar: 50 μm. J Quantification of CD8α + positive cell ratio (%) relative to total DAPI + nucleated cells per section ( n = 6). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001
    Figure Legend Snippet: PF4 remodels the TIME and suppresses tumor growth. A , B Tumor growth curves and terminal tumor weights in C57BL/6 mice bearing AKR or MC38 tumors with or without Pf4 overexpression, treated with or without motolimod administered every three days ( n = 6). C Percentage of CD45 + cells among live cells in AKR and MC38 tumor models ( n = 6). D Percentage of cCD4 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). E Percentage of CD8 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). F Percentage of Tregs within the CD45 + population in AKR and MC38 tumor models ( n = 6). G Ratios of cCD4 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). H Ratios of CD8 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). I Representative immunofluorescence staining of CD8α (red) and DAPI (blue) in MC38-Vector or MC38-Pf4-OE tumor sections with or without motolimod treatment. Scale bar: 50 μm. J Quantification of CD8α + positive cell ratio (%) relative to total DAPI + nucleated cells per section ( n = 6). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Techniques Used: Over Expression, Immunofluorescence, Staining, Plasmid Preparation

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Disrupting the dangerous alliance: Dual anti-inflammatory and anticoagulant strategy targets platelet-neutrophil crosstalk in sepsis.
    Article Snippet: Sepsis is a life-threatening disease characterized by excessive systemic inflammation and coagulopathy.. Platelets and neutrophils form a “dangerous alliance” through crosstalk, promoting the inflammatory cytokine storm and coagulation disorders during sepsis.. Platelet-neutrophil crosstalk leads to the formation of platelet-neutrophil complexes (PNCs), which are the central “protagonists” of this “dangerous alliance.” These PNCs further enhance the crosstalk between platelets and neutrophils, amplifying immune and coagulation responses through positive feedback loops.

    Article Title: Relieving thrombo-inflammation with acid-triggered polymersomes toward ischemic stroke therapy
    Article Snippet: In acute ischemic stroke, neutrophils contribute to ischemia-reperfusion injury through producing neutrophil extracellular traps (NETs), which promote the interaction of platelets and neutrophils to elicit thromboinflammation and facilitate further infarct development.. As the primary degrader of NETs, DNase 1 is restricted by easy deactivation and low efficiency to enrich in the ischemic brain.. Herein, a pH-triggered polymersome nanoplatform is fabricated for enhanced brain delivery of DNase 1 to relieve ischemic stroke-related thrombo-inflammation.

    other:

    Article Title: Liquiritigenin attenuates thrombosis by inhibiting P2Y 12 R-mediated Src/PLCγ2 signaling and cytoplasmic Ca 2+ mobilization in platelets.
    Article Snippet: Background: Cardiovascular and cerebrovascular diseases are the leading causes of death worldwide.. Pathological thrombosis is a major underlying mechanism, where excessive platelet activation triggered by vascular injury constitutes a key event.. Liquiritigenin, a key flavonoid constituent of Glycyrrhiza glabra l., has been reported to possess diverse pharmacological properties, including anti-inflammatory, anti-tumor, neuroprotective, and cardiovascular protective effects.

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms.
    Article Snippet: Firefly and Renilla luciferase activities were measured with the Dual-Luciferase Reporter Assay System (Promega, #E1910) according to the manufacturer’s instructions.

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms
    Article Snippet: Firefly and Renilla luciferase activities were measured with the Dual-Luciferase Reporter Assay System (Promega, #E1910) according to the manufacturer’s instructions.



    Similar Products

    94
    Cusabio e07884m
    E07884m, supplied by Cusabio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+Platelet+Factor+4%2CPF-4+ELISA+Kit/pm42776840-801-24-28
    Average 94 stars, based on 1 article reviews
    e07884m - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    R&D Systems platelet factor 4
    Platelet Factor 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+Thrombopoietin+Quantikine+ELISA+Kit/bio_rxiv__64898__2026__04__01__715884-133-38-41
    Average 94 stars, based on 1 article reviews
    platelet factor 4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology mouse pf4 elisa kit
    TLR8 agonist activates <t>PF4-CXCR3</t> pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01
    Mouse Pf4 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+PF4+(Platelet+Factor+4)+ELISA+Kit/pmc12901762-237-8-12
    Average 94 stars, based on 1 article reviews
    mouse pf4 elisa kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cedarlane anti pf4 h antibody
    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding <t>PF4(P)/heparin(H)</t> antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs <t>(PF4/H/KKO).</t> Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.
    Anti Pf4 H Antibody, supplied by Cedarlane, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Anti-Human+Platelet+Factor+4+(requires+heparin+for+binding)%2C+Purified+(Clone%3A+KKO)+(Mouse+IgG2b)/pmc13712641-59-78-91
    Average 94 stars, based on 1 article reviews
    anti pf4 h antibody - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Agenus Inc anti platelet factor pf 4 antibody formation
    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding <t>PF4(P)/heparin(H)</t> antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs <t>(PF4/H/KKO).</t> Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.
    Anti Platelet Factor Pf 4 Antibody Formation, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/4+antibody+assay+factor+healthtest+heparin+platelet/pmc12777639-84-11-13
    Average 86 stars, based on 1 article reviews
    anti platelet factor pf 4 antibody formation - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology pf4
    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding <t>PF4(P)/heparin(H)</t> antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs <t>(PF4/H/KKO).</t> Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.
    Pf4, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+PF4+(Platelet+Factor+4)+ELISA+Kit/pm41273866-92-5-7
    Average 94 stars, based on 1 article reviews
    pf4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology human pf4 platelet factor 4 elisa kit
    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding <t>PF4(P)/heparin(H)</t> antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs <t>(PF4/H/KKO).</t> Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.
    Human Pf4 Platelet Factor 4 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Human%3FPF4+(Platelet%3FFactor%3F4)%3FELISA%3FKit/pmc12657974-106-17-16
    Average 93 stars, based on 1 article reviews
    human pf4 platelet factor 4 elisa kit - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    TLR8 agonist activates PF4-CXCR3 pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms

    doi: 10.1007/s00262-026-04329-8

    Figure Lengend Snippet: TLR8 agonist activates PF4-CXCR3 pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01

    Article Snippet: Pf4 levels in culture supernatants were quantified using Mouse PF4 ELISA Kit (Elabscience, #E-EL-M3080) according to the manufacturer’s instructions.

    Techniques: Control, Marker, Expressing, Gene Expression, Quantitative Proteomics

    TLR8 agonist induces PF4 expression through NF-κB signaling pathway. A , B qRT-PCR analysis of Pf4 expression in mouse and human macrophages in the motolimod-treated and control groups ( n = 3). C , D Luminescence assay showing NF-κB pathway activation in mouse and human macrophages following motolimod stimulation ( n = 3). E , F qRT-PCR analysis of Rela expression in Rela -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). G , H Western blotting showing p65 protein levels in RELA -knockdown and control mouse and human macrophages with or without motolimod treatment. I , J qRT-PCR analysis of Pf4 / PF4 expression in Rela / RELA -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). K ELISA quantification of Pf4 levels in the culture supernatant from Rela -knockdown and control mouse macrophages with or without motolimod treatment ( n = 3). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms

    doi: 10.1007/s00262-026-04329-8

    Figure Lengend Snippet: TLR8 agonist induces PF4 expression through NF-κB signaling pathway. A , B qRT-PCR analysis of Pf4 expression in mouse and human macrophages in the motolimod-treated and control groups ( n = 3). C , D Luminescence assay showing NF-κB pathway activation in mouse and human macrophages following motolimod stimulation ( n = 3). E , F qRT-PCR analysis of Rela expression in Rela -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). G , H Western blotting showing p65 protein levels in RELA -knockdown and control mouse and human macrophages with or without motolimod treatment. I , J qRT-PCR analysis of Pf4 / PF4 expression in Rela / RELA -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). K ELISA quantification of Pf4 levels in the culture supernatant from Rela -knockdown and control mouse macrophages with or without motolimod treatment ( n = 3). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Article Snippet: Pf4 levels in culture supernatants were quantified using Mouse PF4 ELISA Kit (Elabscience, #E-EL-M3080) according to the manufacturer’s instructions.

    Techniques: Expressing, Quantitative RT-PCR, Control, Luminescence Assay, Activation Assay, Knockdown, Western Blot, Enzyme-linked Immunosorbent Assay

    PF4 remodels the TIME and suppresses tumor growth. A , B Tumor growth curves and terminal tumor weights in C57BL/6 mice bearing AKR or MC38 tumors with or without Pf4 overexpression, treated with or without motolimod administered every three days ( n = 6). C Percentage of CD45 + cells among live cells in AKR and MC38 tumor models ( n = 6). D Percentage of cCD4 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). E Percentage of CD8 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). F Percentage of Tregs within the CD45 + population in AKR and MC38 tumor models ( n = 6). G Ratios of cCD4 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). H Ratios of CD8 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). I Representative immunofluorescence staining of CD8α (red) and DAPI (blue) in MC38-Vector or MC38-Pf4-OE tumor sections with or without motolimod treatment. Scale bar: 50 μm. J Quantification of CD8α + positive cell ratio (%) relative to total DAPI + nucleated cells per section ( n = 6). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms

    doi: 10.1007/s00262-026-04329-8

    Figure Lengend Snippet: PF4 remodels the TIME and suppresses tumor growth. A , B Tumor growth curves and terminal tumor weights in C57BL/6 mice bearing AKR or MC38 tumors with or without Pf4 overexpression, treated with or without motolimod administered every three days ( n = 6). C Percentage of CD45 + cells among live cells in AKR and MC38 tumor models ( n = 6). D Percentage of cCD4 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). E Percentage of CD8 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). F Percentage of Tregs within the CD45 + population in AKR and MC38 tumor models ( n = 6). G Ratios of cCD4 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). H Ratios of CD8 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). I Representative immunofluorescence staining of CD8α (red) and DAPI (blue) in MC38-Vector or MC38-Pf4-OE tumor sections with or without motolimod treatment. Scale bar: 50 μm. J Quantification of CD8α + positive cell ratio (%) relative to total DAPI + nucleated cells per section ( n = 6). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Article Snippet: Pf4 levels in culture supernatants were quantified using Mouse PF4 ELISA Kit (Elabscience, #E-EL-M3080) according to the manufacturer’s instructions.

    Techniques: Over Expression, Immunofluorescence, Staining, Plasmid Preparation

    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding PF4(P)/heparin(H) antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs (PF4/H/KKO). Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.

    Journal: Methods in molecular biology (Clifton, N.J.)

    Article Title: Methods to examine complement activation by HIT immune complexes

    doi: 10.1007/978-1-0716-5376-0_10

    Figure Lengend Snippet: (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding PF4(P)/heparin(H) antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs (PF4/H/KKO). Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.

    Article Snippet: 2.1.1 Complement activation in plasma or whole blood Fresh or frozen healthy donor plasma prepared from healthy donor whole blood collected in acid-citrate-dextrose solution A (ACD-A) or whole blood collected in ACD-A {Baxter Healthcare Corporation, Deerfield, IL, Trisodium citrate, 22.0 g/L (85.3 mM), citric acid, 8.0 g/L (41.6 mM), and dextrose, 24.5 g/L (136 mM)} using the ratio of ACD-A to blood as 1:7 (v/v). ( see Notes 1 – 4 ) 1.5 ml micro-centrifuge tubes Capture antibody: Anti-PF4/H antibody (KKO, a monoclonal anti-PF4/heparin antibody [ 13 ]; catalog # CL2767AP, Cedarlane) Patient and control antibodies (purified IgG or frozen plasma/serum samples) Platelet factor 4 (PF4, Abcam).

    Techniques: Immunoaffinity Purification, Activation Assay, Clinical Proteomics, Incubation, Blocking Assay, Concentration Assay, In Situ, Generated